Dr. Daniel Haller, discusses new study showing aspirin use after colorectal cancer diagnosis may reduce recurrence

MedPage Today

Daniel Haller, MD, a professor and associate chief for clinical affairs in the division of Hematology-Oncology, is quoted in a MedPage Today story about a new study showing that aspirin taken regularly after the diagnosis of colorectal cancer appears to reduce the likelihood of recurrence and the risk of death from colon cancer, among patients whose cancer overexpressed cyclooxygenase 2 (COX-2). Although the data are impressive, Haller says that, as an observational study, the findings likely do not rise to the level needed to change clinical guidelines. Haller is also featured in an audio report accompanying the story, in which he notes that the new study fits into previous findings suggesting that changing colorectal cancer patients’ environment can play a key role in preventing recurrences and new tumor development: “This study appears to nicely close one more loop and says that other things that reduce our risk of colon cancer can also reduce our risk of recurrence of colon cancer.” Read More